Actively Recruiting
A Clinical Trial to Assess COM503 in Participants With Advanced Solid Malignancies
Led by Compugen Ltd · Updated on 2026-02-27
200
Participants Needed
11
Research Sites
149 weeks
Total Duration
On this page
Sponsors
C
Compugen Ltd
Lead Sponsor
G
Gilead Sciences
Collaborating Sponsor
AI-Summary
What this Trial Is About
The overall goal of this first-in-human (FIH) clinical trial is to learn about the safety and dosing of COM503 when given alone or in combination with zimberelimab in participants with advanced solid tumors. The primary objectives of this study are: * To assess the safety and tolerability of COM503 as monotherapy and COM503 in combination with zimberelimab in participants with advanced solid tumors. * To identify the maximum tolerated dose (MTD) / maximum administered dose (MAD) and/or the recommended phase 2 dose (RP2D) of COM503 as monotherapy and in combination with zimberelimab in participants with advanced solid tumors.
CONDITIONS
Official Title
A Clinical Trial to Assess COM503 in Participants With Advanced Solid Malignancies
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants with confirmed advanced recurrent or metastatic solid tumor malignancy
- For dose escalation: disease progression after all standard care therapies
- For dose expansion: disease progression after at least one standard therapy, or standard therapy ineffective, intolerable, or inappropriate, or investigational agent recognized as standard care
- Solid tumor measurable by CT or MRI per RECIST 1.1 criteria assessed by investigator
You will not qualify if you...
- History of another malignancy within 2 years unless treated with curative intent and low risk of recurrence (e.g., nonmelanoma skin cancer, excised carcinoma in situ)
- Use of immunosuppressive systemic medications (e.g., steroids >10 mg/day prednisone) within 2 weeks before trial treatment
- Known active central nervous system metastases or leptomeningeal disease
- Active bacterial, fungal, or viral infection requiring systemic treatment
- Symptomatic ascites or pleural effusion needing drainage within 2 weeks before trial treatment
- Active hepatitis B, hepatitis C, or HIV infection
- Any medical condition posing undue risk per investigator or sponsor judgement
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 11 locations
1
Yale- New Haven Hospital- Yale Cancer Center
New Haven, Connecticut, United States, 06510
Actively Recruiting
2
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States, 0221502215
Actively Recruiting
3
START Midwest
Grand Rapids, Michigan, United States, 49546
Actively Recruiting
4
The West Clinic, PLCC dba West Cancer Center
Germantown, Tennessee, United States, 38138
Actively Recruiting
5
NEXT Oncology San Antonio
San Antonio, Texas, United States, 78229
Actively Recruiting
6
START
San Antonio, Texas, United States, 78229
Actively Recruiting
7
NEXT Oncology Virginia
Fairfax, Virginia, United States, 22031
Actively Recruiting
8
Rambam Health Care Campus
Haifa, Israel, Israel, 3109601
Actively Recruiting
9
Hadassah University Medical Center- Ein Kerem
Jerusalem, Israel, Israel, 9112001
Actively Recruiting
10
Rabin Medical Center
Petah Tikva, Israel, Israel, 4941492
Actively Recruiting
11
The Chaim Sheba Medical Center
Ramat Gan, Israel, Israel, 5465601
Actively Recruiting
Research Team
M
Michelle Chief Medical Officer, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
5
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here